person · Reporting owner

Greene John

Disclosed activity across 4 companies

Tapewire entity: 40058
SEC CIK: 0001610732

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CRISPR Therapeutics AGCRSP · Entity 3852	Director	June 05, 2026	June 09, 2026
NORTHROP GRUMMAN CORP /DE/NOC · Entity 2963	CVP & Chief Financial Officer	February 11, 2026	February 13, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CRISPR Therapeutics AG

Report date June 05, 2026 · Filed June 09, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.84 · Expires 2036-06-05	Direct	13,000	Reported balance After 2026-06-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-05 · Grant · Acquired 13,000 · Balance 13,000 F1: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.

Filing footnotes · ownership attribution and instrument terms

F1: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting.

NORTHROP GRUMMAN CORP /DE/

Report date February 11, 2026 · Filed February 13, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Performance Stock RightsSEC Table II · derivative / convertible security	Direct	4,981	Reported balance After 2026-02-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-02-11 · Grant · Acquired 4,981 · Balance 4,981 F1: Each Restricted Performance Stock Right ("RPSR") represents a contingent right to receive an equivalent number of shares of Issuer common stock, or, at the Issuer's election, cash or a combination of cash and Issuer common stock. The RPSRs vest if the applicable performance metric is satisfied for the relevant measurement period. Grants awarded pursuant to Rule 16b-3(d). F2: The RPSRs acquired include 4,981 unvested RPSRs granted under the 2024 Long-Term Incentive Stock Plan ("2024 LTISP) on 2/11/26 with a measurement period ending on 12/31/28.
Restricted Stock RightsSEC Table II · derivative / convertible security	Direct	5,362	Reported balance After 2026-02-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-02-11 · Grant · Acquired 5,362 · Balance 5,362 F3: Each Restricted Stock Right ("RSR") represents a contingent right to receive an equivalent number of shares in Issuer common stock, or, at the election of the Issuer's Compensation Committee, cash or a combination of cash and Issuer common stock. F4: The RSRs were granted under the 2024 LTISP on 2/11/26 and will vest on 2/12/29. F5: Total amount includes (i) 2,298 RSRs granted under the 2024 LTISP on 2/11/26 that will vest on 2/12/29; (ii) 1,532 RSRs granted under the 2024 LTISP on 2/11/26 that will vest on 2/11/27; and (iii) 1,532 RSRs granted under the 2024 LTISP on 2/11/26 that will vest on 2/11/28.

Filing footnotes · ownership attribution and instrument terms

F1: Each Restricted Performance Stock Right ("RPSR") represents a contingent right to receive an equivalent number of shares of Issuer common stock, or, at the Issuer's election, cash or a combination of cash and Issuer common stock. The RPSRs vest if the applicable performance metric is satisfied for the relevant measurement period. Grants awarded pursuant to Rule 16b-3(d).

F2: The RPSRs acquired include 4,981 unvested RPSRs granted under the 2024 Long-Term Incentive Stock Plan ("2024 LTISP) on 2/11/26 with a measurement period ending on 12/31/28.

F3: Each Restricted Stock Right ("RSR") represents a contingent right to receive an equivalent number of shares in Issuer common stock, or, at the election of the Issuer's Compensation Committee, cash or a combination of cash and Issuer common stock.

F4: The RSRs were granted under the 2024 LTISP on 2/11/26 and will vest on 2/12/29.

F5: Total amount includes (i) 2,298 RSRs granted under the 2024 LTISP on 2/11/26 that will vest on 2/12/29; (ii) 1,532 RSRs granted under the 2024 LTISP on 2/11/26 that will vest on 2/11/27; and (iii) 1,532 RSRs granted under the 2024 LTISP on 2/11/26 that will vest on 2/11/28.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Bioverativ Inc.

Report date March 08, 2018 · Filed March 08, 2018

Section 16 reporting ended · disclosed 2018-03-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-03-08 transaction · row 1 1 source row Row 1 · 2018-03-08 · Disposition to issuer · Disposed 5,951.011 · Balance 0 F1: Includes 454.9542 shares acquired under the Company's Employee Stock Purchase Plan on March 6, 2018. F2: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $105.00 in cash.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2018-03-08 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-03-08 · Disposition to issuer · Disposed 14,230 · Balance 0 F3: Each restricted stock unit ("RSU") represents a contingent right to receive one Share of the issuer's common stock. F4: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2018-03-08 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-03-08 · Disposition to issuer · Disposed 42,727 · Balance 0 F3: Each restricted stock unit ("RSU") represents a contingent right to receive one Share of the issuer's common stock. F4: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes.
Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $44.51	Direct	Reported balance After 2018-03-08 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-03-08 · Disposition to issuer · Disposed 113,230 · Balance 0 F5: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option.
Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $44.51	Direct	Reported balance After 2018-03-08 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-03-08 · Disposition to issuer · Disposed 56,615 · Balance 0 F5: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option.

Filing footnotes · ownership attribution and instrument terms

F1: Includes 454.9542 shares acquired under the Company's Employee Stock Purchase Plan on March 6, 2018.

F2: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $105.00 in cash.

F3: Each restricted stock unit ("RSU") represents a contingent right to receive one Share of the issuer's common stock.

F4: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes.

F5: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option.

Discover Financial Services

Report date May 18, 2025 · Filed May 19, 2025

Section 16 reporting ended · disclosed 2025-05-19. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2025-05-18 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2025-05-18 · Disposition to issuer · Disposed 79,943 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 19, 2024, by and among the Issuer, Capital One Financial Corporation ("Capital One"), and Vega Merger Sub, Inc. ("Merger Sub") (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, at the effective time of the merger (the "Effective Time") between the Issuer and Merger Sub (the "Merger"), each share of Issuer common stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive 1.0192 shares of Capital One common stock (the "Exchange Ratio"). The Merger closed on May 18, 2025 (the "Closing Date"). The closing price of Capital One common stock on the New York Stock Exchange on the last trading day prior to the Closing Date was $197.22. All fractional shares were paid in cash. F2: Includes 42,023 shares of Issuer common stock in respect of restricted stock unit awards (the "Issuer RSU Awards"). Pursuant to the Merger Agreement, at the Effective Time, each Issuer RSU Award outstanding immediately prior to the Effective Time was converted into a Capital One restricted stock unit award in respect of that number of shares of Capital One common stock (rounded to the nearest whole share) equal to the product of (i) the total number of shares of Issuer common stock subject to the Issuer RSU Award immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, and which is otherwise be subject to the same terms and conditions as applied to the corresponding Issuer RSU Award immediately prior to the Effective Time. F3: Includes 77.4 shares of Issuer common stock acquired under the Discover Financial Services Employee Stock Purchase Plan for the periods beginning January 1, 2025 and ending March 31, 2025 and beginning April 1, 2025 and ending May 5, 2025. F4: As a result of the Merger, the Reporting Person no longer beneficially owns, directly or indirectly, any shares of Issuer common stock.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 19, 2024, by and among the Issuer, Capital One Financial Corporation ("Capital One"), and Vega Merger Sub, Inc. ("Merger Sub") (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, at the effective time of the merger (the "Effective Time") between the Issuer and Merger Sub (the "Merger"), each share of Issuer common stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive 1.0192 shares of Capital One common stock (the "Exchange Ratio"). The Merger closed on May 18, 2025 (the "Closing Date"). The closing price of Capital One common stock on the New York Stock Exchange on the last trading day prior to the Closing Date was $197.22. All fractional shares were paid in cash.

F2: Includes 42,023 shares of Issuer common stock in respect of restricted stock unit awards (the "Issuer RSU Awards"). Pursuant to the Merger Agreement, at the Effective Time, each Issuer RSU Award outstanding immediately prior to the Effective Time was converted into a Capital One restricted stock unit award in respect of that number of shares of Capital One common stock (rounded to the nearest whole share) equal to the product of (i) the total number of shares of Issuer common stock subject to the Issuer RSU Award immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, and which is otherwise be subject to the same terms and conditions as applied to the corresponding Issuer RSU Award immediately prior to the Effective Time.

F3: Includes 77.4 shares of Issuer common stock acquired under the Discover Financial Services Employee Stock Purchase Plan for the periods beginning January 1, 2025 and ending March 31, 2025 and beginning April 1, 2025 and ending May 5, 2025.

F4: As a result of the Merger, the Reporting Person no longer beneficially owns, directly or indirectly, any shares of Issuer common stock.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 05, 2026 Filed Jun 9, 2026 21:43 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	GrantStock Option (Right to Buy) · Derivative	13,000	$0.00 Strike: $51.84	$0.00	Disclosure SEC source: 0001193125-26-264288 · ownership.xml · derivative · entry 1 Greene John · CIK 0001610732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Shares · 13,000 shares Expires 2036-06-05 F1 · derivative.exercise_date: Subject to continued service to the Company or any of its subsidiaries, the options will vest and become exercisable in 12 equal monthly installments on the final day of each succeeding calendar month occurring after the grant date provided that the first installment vests on June 30, 2026 and the last installment vests on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2027 Annual Meeting. Read SEC document
February 11, 2026 Filed Feb 13, 2026 21:15 UTC	NORTHROP GRUMMAN CORP /DE/ NOC · Entity 2963	GrantRestricted Stock Rights · Derivative	5,362	$0.00	$0.00	Disclosure SEC source: 0001628280-26-008122 · wk-form4_1771017352.xml · derivative · entry 2 Greene John · CIK 0001610732 · CVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,362 Underlying: Common Stock · 5,362 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Right ("RSR") represents a contingent right to receive an equivalent number of shares in Issuer common stock, or, at the election of the Issuer's Compensation Committee, cash or a combination of cash and Issuer common stock. F3 · derivative.exercise_date: Each Restricted Stock Right ("RSR") represents a contingent right to receive an equivalent number of shares in Issuer common stock, or, at the election of the Issuer's Compensation Committee, cash or a combination of cash and Issuer common stock. F4 · derivative.expiration_date: The RSRs were granted under the 2024 LTISP on 2/11/26 and will vest on 2/12/29. F5 · balance_after: Total amount includes (i) 2,298 RSRs granted under the 2024 LTISP on 2/11/26 that will vest on 2/12/29; (ii) 1,532 RSRs granted under the 2024 LTISP on 2/11/26 that will vest on 2/11/27; and (iii) 1,532 RSRs granted under the 2024 LTISP on 2/11/26 that will vest on 2/11/28. Read SEC document
February 11, 2026 Filed Feb 13, 2026 21:15 UTC	NORTHROP GRUMMAN CORP /DE/ NOC · Entity 2963	GrantRestricted Performance Stock Rights · Derivative	4,981	$0.00	$0.00	Disclosure SEC source: 0001628280-26-008122 · wk-form4_1771017352.xml · derivative · entry 1 Greene John · CIK 0001610732 · CVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,981 Underlying: Common Stock · 4,981 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Performance Stock Right ("RPSR") represents a contingent right to receive an equivalent number of shares of Issuer common stock, or, at the Issuer's election, cash or a combination of cash and Issuer common stock. The RPSRs vest if the applicable performance metric is satisfied for the relevant measurement period. Grants awarded pursuant to Rule 16b-3(d). F2 · shares: The RPSRs acquired include 4,981 unvested RPSRs granted under the 2024 Long-Term Incentive Stock Plan ("2024 LTISP) on 2/11/26 with a measurement period ending on 12/31/28. F1 · derivative.exercise_date: Each Restricted Performance Stock Right ("RPSR") represents a contingent right to receive an equivalent number of shares of Issuer common stock, or, at the Issuer's election, cash or a combination of cash and Issuer common stock. The RPSRs vest if the applicable performance metric is satisfied for the relevant measurement period. Grants awarded pursuant to Rule 16b-3(d). F1 · derivative.expiration_date: Each Restricted Performance Stock Right ("RPSR") represents a contingent right to receive an equivalent number of shares of Issuer common stock, or, at the Issuer's election, cash or a combination of cash and Issuer common stock. The RPSRs vest if the applicable performance metric is satisfied for the relevant measurement period. Grants awarded pursuant to Rule 16b-3(d). F2 · balance_after: The RPSRs acquired include 4,981 unvested RPSRs granted under the 2024 Long-Term Incentive Stock Plan ("2024 LTISP) on 2/11/26 with a measurement period ending on 12/31/28. Read SEC document
June 05, 2025 Filed Jun 6, 2025 21:30 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	GrantStock Option (Right to Buy) · Derivative	13,000	$0.00 Strike: $38.57	$0.00	Disclosure SEC source: 0000950170-25-083270 · ownership.xml · derivative · entry 1 Greene John · CIK 0001610732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Shares · 13,000 shares Expires 2035-06-05 F1 · derivative.exercise_date: This option was granted on June 5, 2025 with respect to 13,000 Common Shares, with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2025; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2026 Annual General Meeting of Shareholders. Read SEC document
May 18, 2025 Filed May 19, 2025 21:15 UTC	Discover Financial Services DFS · Entity 13531	Disposition to issuerCommon Stock	79,943	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-25-074571 · ownership.xml · nonDerivative · entry 1 Greene John · CIK 0001610732 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 19, 2024, by and among the Issuer, Capital One Financial Corporation ("Capital One"), and Vega Merger Sub, Inc. ("Merger Sub") (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, at the effective time of the merger (the "Effective Time") between the Issuer and Merger Sub (the "Merger"), each share of Issuer common stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive 1.0192 shares of Capital One common stock (the "Exchange Ratio"). The Merger closed on May 18, 2025 (the "Closing Date"). The closing price of Capital One common stock on the New York Stock Exchange on the last trading day prior to the Closing Date was $197.22. All fractional shares were paid in cash. F2 · shares: Includes 42,023 shares of Issuer common stock in respect of restricted stock unit awards (the "Issuer RSU Awards"). Pursuant to the Merger Agreement, at the Effective Time, each Issuer RSU Award outstanding immediately prior to the Effective Time was converted into a Capital One restricted stock unit award in respect of that number of shares of Capital One common stock (rounded to the nearest whole share) equal to the product of (i) the total number of shares of Issuer common stock subject to the Issuer RSU Award immediately prior to the Effective Time multiplied by (ii) the Exchange Ratio, and which is otherwise be subject to the same terms and conditions as applied to the corresponding Issuer RSU Award immediately prior to the Effective Time. F3 · shares: Includes 77.4 shares of Issuer common stock acquired under the Discover Financial Services Employee Stock Purchase Plan for the periods beginning January 1, 2025 and ending March 31, 2025 and beginning April 1, 2025 and ending May 5, 2025. F1 · price: Disposed of pursuant to the Agreement and Plan of Merger, dated as of February 19, 2024, by and among the Issuer, Capital One Financial Corporation ("Capital One"), and Vega Merger Sub, Inc. ("Merger Sub") (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, at the effective time of the merger (the "Effective Time") between the Issuer and Merger Sub (the "Merger"), each share of Issuer common stock issued and outstanding immediately prior to the Effective Time was converted into the right to receive 1.0192 shares of Capital One common stock (the "Exchange Ratio"). The Merger closed on May 18, 2025 (the "Closing Date"). The closing price of Capital One common stock on the New York Stock Exchange on the last trading day prior to the Closing Date was $197.22. All fractional shares were paid in cash. F4 · balance_after: As a result of the Merger, the Reporting Person no longer beneficially owns, directly or indirectly, any shares of Issuer common stock. Read SEC document
February 26, 2025 Filed Feb 28, 2025 22:35 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	PurchaseCommon Shares	7,000	$44.85	$313,947.90	Disclosure SEC source: 0000950170-25-030181 · ownership.xml · nonDerivative · entry 1 Greene John · CIK 0001610732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 F1 · kind: Open market purchase of shares in accordance with Issuer's trading policies. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.84 to $44.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document
February 01, 2025 Filed Feb 4, 2025 21:39 UTC	Discover Financial Services DFS · Entity 13531	Tax withholdingCommon Stock	1,840	$201.09	$370,005.60	Disclosure SEC source: 0000950170-25-013589 · ownership.xml · nonDerivative · entry 1 Greene John · CIK 0001610732 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,866 F1 · shares: Number of shares withheld to pay the tax withholding obligation incurred in connection with the vesting of previously granted restricted stock units. Read SEC document
January 23, 2025 Filed Jan 27, 2025 23:54 UTC	Discover Financial Services DFS · Entity 13531	GrantCommon Stock	14,630	$0.00	$0.00	Disclosure SEC source: 0000950170-25-009357 · ownership.xml · nonDerivative · entry 1 Greene John · CIK 0001610732 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,706 F1 · shares: Award of restricted stock units pursuant to the Discover Financial Services 2023 Omnibus Incentive Plan. Read SEC document
December 19, 2024 Filed Dec 23, 2024 22:16 UTC	Discover Financial Services DFS · Entity 13531	Tax withholdingCommon Stock	11,702	$169.27	$1,980,797.54	Disclosure SEC source: 0000950170-24-139707 · ownership.xml · nonDerivative · entry 2 Greene John · CIK 0001610732 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,076 F3 · shares: Shares withheld to satisfy the tax withholding obligation incurred in connection with the accelerated vesting of previously granted performance stock units and restricted stock units. Read SEC document
December 19, 2024 Filed Dec 23, 2024 22:16 UTC	Discover Financial Services DFS · Entity 13531	GrantCommon Stock	12,109	$0.00	$0.00	Disclosure SEC source: 0000950170-24-139707 · ownership.xml · nonDerivative · entry 1 Greene John · CIK 0001610732 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,778 F1 · shares: Shares acquired upon the accelerated vesting of performance stock units awarded in 2022. F2 · balance_after: Includes 190.89 shares aquired under the Discover Financial Services Employee Stock Purchase Plan ("ESPP") for the period beginning January 1, 2024 and ending September 30, 2024. No shares were acquired under the ESPP for the period beginning October 1, 2023 and ending December 31, 2023. Read SEC document
May 30, 2024 Filed May 31, 2024 20:15 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	GrantStock Option (Right to Buy) · Derivative	13,000	$0.00 Strike: $54.06	$0.00	Disclosure SEC source: 0000950170-24-067324 · ownership.xml · derivative · entry 1 Greene John · CIK 0001610732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Shares · 13,000 shares Expires 2034-05-30 F1 · derivative.exercise_date: This option was granted on May 30, 2024 with respect to 13,000 Common Shares, with 100% of the shares vesting in 12 equal monthly installments beginning on May 31, 2024; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2025 Annual General Meeting of Shareholders. Read SEC document
February 22, 2024 Filed Feb 26, 2024 22:17 UTC	Discover Financial Services DFS · Entity 13531	GrantCommon Stock	9,051	$0.00	$0.00	Disclosure SEC source: 0000950170-24-020305 · ownership.xml · nonDerivative · entry 2 Greene John · CIK 0001610732 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,478 F2 · shares: Special retention award of restricted stock units pursuant to the Discover Financial Services 2023 Omnibus Incentive Plan. Read SEC document
February 22, 2024 Filed Feb 26, 2024 22:17 UTC	Discover Financial Services DFS · Entity 13531	GrantCommon Stock	29,324	$0.00	$0.00	Disclosure SEC source: 0000950170-24-020305 · ownership.xml · nonDerivative · entry 1 Greene John · CIK 0001610732 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,427 F1 · shares: Award of restricted stock units pursuant to the Discover Financial Services 2023 Omnibus Incentive Plan. Read SEC document
February 01, 2024 Filed Feb 6, 2024 02:27 UTC	Discover Financial Services DFS · Entity 13531	Tax withholdingCommon Stock	12,290	$106.56	$1,309,622.40	Disclosure SEC source: 0001209191-24-002874 · doc4.xml · nonDerivative · entry 2 Greene John · CIK 0001610732 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,103 F1 · shares: Number of shares withheld to pay the tax withholding obligation incurred in connection with the vesting of previously granted performance stock units and restricted stock units. Read SEC document
February 01, 2024 Filed Feb 6, 2024 02:27 UTC	Discover Financial Services DFS · Entity 13531	GrantCommon Stock	21,801	$0.00	$0.00	Disclosure SEC source: 0001209191-24-002874 · doc4.xml · nonDerivative · entry 1 Greene John · CIK 0001610732 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,393 Read SEC document
February 01, 2024 Filed Feb 6, 2024 02:22 UTC	Discover Financial Services DFS · Entity 13531	Tax withholdingCommon Stock	12,290	$106.56	$1,309,622.40	Disclosure SEC source: 0001209191-24-002867 · doc4.xml · nonDerivative · entry 2 Greene John · CIK 0001610732 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,103 F1 · shares: Number of shares withheld to pay the tax withholding obligation incurred in connection with the vesting of previously granted performance stock units and restricted stock units. Read SEC document
February 01, 2024 Filed Feb 6, 2024 02:22 UTC	Discover Financial Services DFS · Entity 13531	GrantCommon Stock	21,801	$0.00	$0.00	Disclosure SEC source: 0001209191-24-002867 · doc4.xml · nonDerivative · entry 1 Greene John · CIK 0001610732 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,393 Read SEC document
January 26, 2024 Filed Jan 30, 2024 21:24 UTC	Discover Financial Services DFS · Entity 13531	SaleCommon Stock	35,191	$106.51	$3,748,193.41	Disclosure SEC source: 0001209191-24-002412 · doc4.xml · nonDerivative · entry 1 Greene John · CIK 0001610732 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,592 F1 · price: Reflects weighted average sale price for open-market sales transaction reported herein. Actual sales prices ranged from $106.31 to $106.71. The reporting person provided to the issuer, and will provide any security holder of Discover Financial Services or member of the SEC staff, full information regarding the number of shares sold at each separate price upon request. F2 · balance_after: Includes 244.43 shares acquired under the Discover Financial Services Employee Stock Purchase Plan for the period beginning January 1, 2023 and ending on September 30, 2023. Read SEC document
June 08, 2023 Filed Jun 9, 2023 21:34 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	GrantStock Option (Right to Buy) · Derivative	13,000	$0.00 Strike: $62.59	$0.00	Disclosure SEC source: 0001209191-23-035977 · doc4.xml · derivative · entry 1 Greene John · CIK 0001610732 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,000 Underlying: Common Shares · 13,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: This option was granted on June 8, 2023 with respect to 13,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2023; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2024 Annual General Meeting of Shareholders. Read SEC document
February 23, 2023 Filed Feb 27, 2023 21:06 UTC	Discover Financial Services DFS · Entity 13531	GrantCommon Stock	9,960	$0.00	$0.00	Disclosure SEC source: 0001209191-23-013158 · doc4.xml · nonDerivative · entry 1 Greene John · CIK 0001610732 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,539 Read SEC document
February 01, 2023 Filed Feb 3, 2023 21:17 UTC	Discover Financial Services DFS · Entity 13531	Tax withholdingCommon Stock	14,083	$115.83	$1,631,233.89	Disclosure SEC source: 0001209191-23-006820 · doc4.xml · nonDerivative · entry 2 Greene John · CIK 0001610732 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,579 F2 · shares: Number of shares withheld to pay the tax withholding obligation incurred in connection with the vesting of previously granted performance stock units and restricted stock units. Read SEC document
February 01, 2023 Filed Feb 3, 2023 21:17 UTC	Discover Financial Services DFS · Entity 13531	GrantCommon Stock	25,196	$0.00	$0.00	Disclosure SEC source: 0001209191-23-006820 · doc4.xml · nonDerivative · entry 1 Greene John · CIK 0001610732 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,662 F1 · balance_after: Includes 190.5845 shares acquired under the Discover Financial Services Employee Stock Purchase Plan for the period beginning July 1, 2022 and ending on December 31, 2022. Read SEC document
August 01, 2022 Filed Aug 3, 2022 21:35 UTC	Discover Financial Services DFS · Entity 13531	Tax withholdingCommon Stock	1,752	$102.22	$179,089.44	Disclosure SEC source: 0001209191-22-044279 · doc4.xml · nonDerivative · entry 1 Greene John · CIK 0001610732 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,275.4574 F1 · shares: Number of shares withheld to pay the tax withholding obligation incurred in connection with the vesting of previously granted restricted stock units. F2 · balance_after: Includes 75.4574 shares acquired under the Discover Financial Services Employee Stock Purchase Plan for the period beginning April 1, 2022 and ending on June 30, 2022. Read SEC document
June 09, 2022 Filed Jun 10, 2022 21:41 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	GrantStock Option (Right to Buy) · Derivative	12,000	$0.00 Strike: $71.70	$0.00	Disclosure SEC source: 0001209191-22-036045 · doc4.xml · derivative · entry 1 Greene John · CIK 0001610732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Shares · 12,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: This option was granted on June 9, 2022 with respect to 12,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2022; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2023 Annual General Meeting of Shareholders. Read SEC document
February 25, 2022 Filed Mar 1, 2022 22:53 UTC	Discover Financial Services DFS · Entity 13531	GrantCommon Stock	7,339	$0.00	$0.00	Disclosure SEC source: 0001209191-22-014228 · doc4.xml · nonDerivative · entry 1 Greene John · CIK 0001610732 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,952 Read SEC document
February 15, 2022 Filed Feb 17, 2022 22:11 UTC	Discover Financial Services DFS · Entity 13531	SaleCommon Stock	4,443	$127.95	$568,464.08	Disclosure SEC source: 0001209191-22-010877 · doc4.xml · nonDerivative · entry 1 Greene John · CIK 0001610732 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,613 F1 · price: Reflects weighted average sale price for open-market sales transaction reported herein. Actual sales prices ranged from $127.900 to $128.116. The reporting person provided to the issuer, and will provide any security holder of Discover Financial Services or member of the SEC staff, full information regarding the number of shares sold at each separate price upon request Read SEC document
February 01, 2022 Filed Feb 3, 2022 22:49 UTC	Discover Financial Services DFS · Entity 13531	Tax withholdingCommon Stock	2,079	$118.02	$245,363.58	Disclosure SEC source: 0001209191-22-006912 · doc4.xml · nonDerivative · entry 1 Greene John · CIK 0001610732 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,056 F1 · shares: Number of shares withheld to pay the tax withholding obligation incurred in connection with the vesting of previously granted restricted stock units. Read SEC document
August 01, 2021 Filed Aug 3, 2021 21:31 UTC	Discover Financial Services DFS · Entity 13531	Tax withholdingCommon Stock	1,752	$124.32	$217,808.64	Disclosure SEC source: 0001567619-21-014364 · doc1.xml · nonDerivative · entry 1 Greene John · CIK 0001610732 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,135 F1 · shares: Number of shares withheld to pay the tax withholding obligation incurred in connection with the vesting of previously-granted restricted stock units. Read SEC document
June 10, 2021 Filed Jun 14, 2021 21:38 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	GrantStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $123.71	$0.00	Disclosure SEC source: 0001209191-21-040295 · doc4.xml · derivative · entry 1 Greene John · CIK 0001610732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires 2031-06-10 F1 · derivative.exercise_date: This option was granted on June 10, 2021 with respect to 10,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2021; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2022 Annual General Meeting of Shareholders. Read SEC document
February 19, 2021 Filed Feb 24, 2021 00:18 UTC	Discover Financial Services DFS · Entity 13531	GrantCommon Stock	9,690	$0.00	$0.00	Disclosure SEC source: 0001140361-21-005893 · form4.xml · nonDerivative · entry 1 Greene John · CIK 0001610732 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,887 Read SEC document
February 01, 2021 Filed Feb 4, 2021 00:40 UTC	Discover Financial Services DFS · Entity 13531	Tax withholdingCommon Stock	1,146	$82.19	$94,189.74	Disclosure SEC source: 0001140361-21-003306 · form4.xml · nonDerivative · entry 1 Greene John · CIK 0001610732 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,197 F1 · shares: Number of shares withheld to pay the tax withholding obligation incurred in connection with the vesting of previously-granted restricted stock units. Read SEC document
August 01, 2020 Filed Aug 3, 2020 22:33 UTC	Discover Financial Services DFS · Entity 13531	Tax withholdingCommon Stock	1,159	$49.43	$57,289.37	Disclosure SEC source: 0000905148-20-000852 · form4.xml · nonDerivative · entry 1 Greene John · CIK 0001610732 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,343 F1 · shares: Number of shares withheld to pay the tax withholding obligation incurred in connection with the vesting of previously-granted restricted stock units. Read SEC document
June 11, 2020 Filed Jun 15, 2020 20:33 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $59.70	$0.00	Disclosure SEC source: 0001209191-20-036619 · doc4.xml · derivative · entry 1 Greene John · CIK 0001610732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-11 F1 · derivative.exercise_date: This option was granted on June 11, 2020 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on June 30, 2020; provided that the last installment will vest on the earlier of (i) the one year anniversary of the date of grant or (ii) the date of the 2021 Annual General Meeting of Shareholders. Read SEC document
January 27, 2020 Filed Jan 27, 2020 23:28 UTC	Discover Financial Services DFS · Entity 13531	PurchaseCommon Stock	3,377	$73.84	$249,342.82	Disclosure SEC source: 0000905148-20-000170 · form4.xml · nonDerivative · entry 1 Greene John · CIK 0001610732 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,502 Read SEC document
January 22, 2020 Filed Jan 24, 2020 21:10 UTC	Discover Financial Services DFS · Entity 13531	GrantCommon Stock	11,198	$0.00	$0.00	Disclosure SEC source: 0000905148-20-000130 · form4.xml · nonDerivative · entry 1 Greene John · CIK 0001610732 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,125 Read SEC document
September 18, 2019 Filed Sep 20, 2019 20:35 UTC	Discover Financial Services DFS · Entity 13531	GrantCommon Stock	11,861	$0.00	$0.00	Disclosure SEC source: 0000905148-19-000863 · form4.xml · nonDerivative · entry 1 Greene John · CIK 0001610732 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,927 Read SEC document
June 11, 2019 Filed Jun 13, 2019 21:05 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	GrantStock Option (Right to Buy) · Derivative	30,000	$0.00 Strike: $43.52	$0.00	Disclosure SEC source: 0000899243-19-016846 · doc4.xml · derivative · entry 1 Greene John · CIK 0001610732 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-06-11 F1 · derivative.exercise_date: This option was granted on June 11, 2019 with respect to 30,000 Common Shares with 100% of the shares vesting in 36 equal monthly installments. Read SEC document
March 08, 2018 Filed Mar 8, 2018 17:31 UTC	Bioverativ Inc. BIVV · Entity 168487	Disposition to issuerNon-Qualified Stock Option · Derivative	56,615	Not disclosed Strike: $44.51	Not disclosed	Disclosure SEC source: 0001127602-18-010664 · form4.xml · derivative · entry 5 Greene John · CIK 0001610732 · EVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,615 shares Expires not disclosed F5 · shares: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F5 · price: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. Read SEC document
March 08, 2018 Filed Mar 8, 2018 17:31 UTC	Bioverativ Inc. BIVV · Entity 168487	Disposition to issuerNon-Qualified Stock Option · Derivative	113,230	Not disclosed Strike: $44.51	Not disclosed	Disclosure SEC source: 0001127602-18-010664 · form4.xml · derivative · entry 4 Greene John · CIK 0001610732 · EVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 113,230 shares Expires not disclosed F5 · shares: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F5 · price: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. "Option Consideration" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option. Read SEC document
March 08, 2018 Filed Mar 8, 2018 17:31 UTC	Bioverativ Inc. BIVV · Entity 168487	Disposition to issuerRestricted Stock Units · Derivative	42,727	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-18-010664 · form4.xml · derivative · entry 3 Greene John · CIK 0001610732 · EVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,727 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one Share of the issuer's common stock. F4 · shares: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. F4 · price: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. Read SEC document
March 08, 2018 Filed Mar 8, 2018 17:31 UTC	Bioverativ Inc. BIVV · Entity 168487	Disposition to issuerRestricted Stock Units · Derivative	14,230	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-18-010664 · form4.xml · derivative · entry 2 Greene John · CIK 0001610732 · EVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,230 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one Share of the issuer's common stock. F4 · shares: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. F4 · price: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the "Offer") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes. Read SEC document
March 08, 2018 Filed Mar 8, 2018 17:31 UTC	Bioverativ Inc. BIVV · Entity 168487	Disposition to issuerCommon Stock	5,951.011	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-18-010664 · form4.xml · nonDerivative · entry 1 Greene John · CIK 0001610732 · EVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Includes 454.9542 shares acquired under the Company's Employee Stock Purchase Plan on March 6, 2018. F2 · price: Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the "Merger Agreement"), between the Company, Sanofi, a French soci?t? anonyme (the "Parent"), and Blink Acquisition Corp. ("Merger Sub"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a "Share") was converted into the right to receive $105.00 in cash. Read SEC document
February 14, 2018 Filed Feb 15, 2018 22:24 UTC	Bioverativ Inc. BIVV · Entity 168487	Exercise / conversionRestricted Stock Units · Derivative	7,114	$0.00	$0.00	Disclosure SEC source: 0001127602-18-006441 · form4.xml · derivative · entry 3 Greene John · CIK 0001610732 · EVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,230 Underlying: Common Stock · 7,114 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on February 14, 2018. F4 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on February 14, 2018. Read SEC document
February 14, 2018 Filed Feb 15, 2018 22:24 UTC	Bioverativ Inc. BIVV · Entity 168487	Tax withholdingCommon Stock	2,118	$103.52	$219,255.36	Disclosure SEC source: 0001127602-18-006441 · form4.xml · nonDerivative · entry 2 Greene John · CIK 0001610732 · EVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,496.0568 F2 · shares: Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units. Read SEC document
February 14, 2018 Filed Feb 15, 2018 22:24 UTC	Bioverativ Inc. BIVV · Entity 168487	Exercise / conversionCommon Stock	7,114	$0.00	$0.00	Disclosure SEC source: 0001127602-18-006441 · form4.xml · nonDerivative · entry 1 Greene John · CIK 0001610732 · EVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,614.0568 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes an aggregate of 500.0568 shares acquired under the Company's Employee Stock Purchase Plan on April 5, 2017 and July 6, 2017. Read SEC document
January 31, 2018 Filed Feb 2, 2018 22:21 UTC	Bioverativ Inc. BIVV · Entity 168487	GrantRestricted Stock Units · Derivative	42,727	$0.00	$0.00	Disclosure SEC source: 0001127602-18-003823 · form4.xml · derivative · entry 1 Greene John · CIK 0001610732 · EVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,727 Underlying: Common Stock · 42,727 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on January 31, 2019. F2 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on January 31, 2019. Read SEC document
February 14, 2017 Filed Feb 16, 2017 21:41 UTC	Bioverativ Inc. BIVV · Entity 168487	GrantRestricted Stock Units · Derivative	21,344	$0.00	$0.00	Disclosure SEC source: 0001127602-17-006623 · form4.xml · derivative · entry 3 Greene John · CIK 0001610732 · EVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,344 Underlying: Common Stock · 21,344 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F4 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on February 14, 2018. F4 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on February 14, 2018. Read SEC document
February 14, 2017 Filed Feb 16, 2017 21:41 UTC	Bioverativ Inc. BIVV · Entity 168487	GrantNon-Qualified Stock Option · Derivative	113,028	$0.00 Strike: $44.51	$0.00	Disclosure SEC source: 0001127602-17-006623 · form4.xml · derivative · entry 2 Greene John · CIK 0001610732 · EVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,028 Underlying: Common Stock · 113,028 shares Expires 2027-02-14 F2 · derivative.exercise_date: This option vests in full on the third anniversary of the date of grant. Read SEC document
February 14, 2017 Filed Feb 16, 2017 21:41 UTC	Bioverativ Inc. BIVV · Entity 168487	GrantNon-Qualified Stock Option · Derivative	56,514	$0.00 Strike: $44.51	$0.00	Disclosure SEC source: 0001127602-17-006623 · form4.xml · derivative · entry 1 Greene John · CIK 0001610732 · EVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,514 Underlying: Common Stock · 56,514 shares Expires 2027-02-14 F1 · derivative.exercise_date: This option vests in three equal annual installments beginning on February 14, 2018. Read SEC document
February 14, 2017 Filed Mar 27, 2017 20:31 UTC Amendment	Bioverativ Inc. BIVV · Entity 168487	GrantNon-Qualified Stock Option · Derivative	113,230	$0.00 Strike: $44.51	$0.00	Disclosure SEC source: 0001127602-17-012955 · form4a.xml · derivative · entry 2 Greene John · CIK 0001610732 · EVP, CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,230 Underlying: Common Stock · 113,230 shares Expires 2027-02-14 F1 · shares: The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing. F3 · derivative.exercise_date: This option vests in full on the third anniversary of the date of grant. F1 · derivative.underlying_shares: The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing. F1 · balance_after: The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.